Literature DB >> 23888376

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.

Xiaodong Mo1, Xiaojun Huang.   

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially matched related donors (PMRDs) are a valuable option for HSCT. Several protocols (with or without ex vivo T-cell depletion (TCD)) have been established worldwide. TCD including CD34(+) positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity. However, TCD is associated with prolonged immune deficiencies, increased risks of infectious complications, and high transplantation-related mortality. PMRD HSCTwithout ex vivo TCD is well developed, and numerous patients have benefitted from it. Here, we review the literature on PMRD HSCT.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23888376     DOI： 10.1007/s11684-013-0279-x

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  59 in total

1.  Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.

Authors:  X-Y Zhao; Y-J Chang; L-P Xu; D-H Liu; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2009-04-20       Impact factor: 5.483

2.  Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts.

Authors:  X-H Luo; X-J Huang; D Li; K-Y Liu; L-P Xu; D-H Liu
Journal:  Transpl Infect Dis       Date:  2012-02-29       Impact factor: 2.228

3.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.

Authors:  X-J Huang; D-H Liu; K-Y Liu; L-P Xu; H Chen; W Han; Y-H Chen; J-Z Wang; Z-Y Gao; Y-C Zhang; Q Jiang; H-X Shi; D-P Lu
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

4.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.

Authors:  M Weisser; W Kern; S Rauhut; C Schoch; W Hiddemann; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

5.  Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiao-Su Zhao; Yan-Rong Liu; Hong-Hu Zhu; Lan-Ping Xu; Dai-Hong Liu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Ann Hematol       Date:  2011-06-28       Impact factor: 3.673

6.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

7.  New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

Authors:  Susanne Schnittger; Martin Weisser; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

8.  Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation.

Authors:  Xiao-Jun Huang; Jie Zhao; Xiang-Yu Zhao; Ying-Jun Chang
Journal:  Leuk Res       Date:  2008-07-23       Impact factor: 3.156

9.  Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Ming-Rui Huo; Xiao-Jun Huang
Journal:  Transpl Immunol       Date:  2009-05-22       Impact factor: 1.708

10.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han; Yu-Hong Chen; Xiao-Hui Zhang; Dao-Pei Lu
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.